参考文献/References:
[1] 中国营养学会肥胖防控分会,中国营养学会临床营养分会,中华预防医学会行为健康分会,等.中国居民肥胖防治专家共识[J].中华流行病学杂志,2022,43(5):609-626.DOI:10.3760/cma.j.cn112338-20220402-00253.
[2] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.DOI:10.3760/cma.j.cn115791-20210221-00095.
[3] Angelidi AM,Belanger MJ,Kokkinos A,et al.Novel noninvasive approaches to the treatment of obesity:from pharmacotherapy to gene therapy[J].Endocr Rev,2022,43(3):507-557.DOI:10.1210/endrev/bnab034.
[4] Torgerson JS,Hauptman J,Boldrin MN,et al.XENical in the prevention of diabetes in obese subjects(XENDOS)study:a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients[J].Diabetes Care,2004,27(1):155-161.DOI:10.2337/diacare.27.1.155.
[5] Allison DB,Gadde KM,Garvey WT,et al.Controlled-release phentermine/topiramate in severely obese adults:a randomized controlled trial(EQUIP)[J].Obesity(Silver Spring),2012,20(2):330-342.DOI:10.1038/oby.2011.330.
[6] Gadde KM,Allison DB,Ryan DH,et al.Effects of low-dose,controlled-release,phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults(CONQUER):a randomised,placebo-controlled,phase 3 trial[J].Lancet,2011,377(9774):1341-1352.DOI:10.1016/S0140-6736(11)60205-5.
[7] Billes SK,Sinnayah P,Cowley MA.Naltrexone/bupropion for obesity:an investigational combination pharmacotherapy for weight loss[J].Pharmacol Res,2014,84:1-11.DOI:10.1016/j.phrs.2014.04.004.
[8] Greenway FL,FujiokaK,Plodkowski RA,et al.Effect of naltrexone plus bupropion on weight loss in overweight and obese adults(COR-I):a multicentre,randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2010,376(9741):595-605.DOI:10.1016/S0140-6736(10)60888-4.
[9] Apovian CM,Aronne L,Rubino D,et al.A randomized,phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors(COR-II)[J].Obesity(Silver Spring),2013,21(5):935-43.DOI:10.1002/oby.20309.
[10] Brierley DI,Holt MK,Singh A,et al.Central and peripheral GLP-1 systems independently suppress eating[J].Nat Metab,2021,3(2):258-73.DOI:10.1038/s42255-021-00344-4.
[11] Farooqi IS,Jebb SA,Langmack G,et al.Effects of recombinant leptin therapy in a child with congenital leptin deficiency[J].N Engl J Med,1999,341(12):879-884.DOI:10.1056/NEJM199909163411204.
[12] Chu ZL,Carroll C,Alfonso J,et al.A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release[J].Endocrinology,2008,149(5):2038-47.DOI:10.1210/en.2007-0966.
[13] Overton HA,Fyfe MC,Reynet C.GPR119,a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity[J].Br J Pharmacol,2008,153 Suppl 1(Suppl 1):S76-S81.DOI:10.1038/sj.bjp.0707529.
[14] Finan B,Capozzi ME,Campbell JE.Repositioning glucagon action in the physiology and pharmacology of diabetes[J].Diabetes,2020,69(4):532-541.DOI:10.2337/dbi19-0004.
[15] Finan B,Müller TD,Clemmensen C,et al.Reappraisal of GIP pharmacology for metabolic diseases[J].Trends Mol Med,2016,22(5):359-376.DOI:10.1016/j.molmed.2016.03.005.
[16] Chavda VP,Ajabiya J,Teli D,et al.Tirzepatide,a new era of dual-targeted treatment for diabetes and obesity:a mini-review[J].Molecules,2022,27(13):4315.DOI:10.3390/molecules27134315.
[17] Jastreboff AM,Aronne LJ,Ahmad NN,et al.Tirzepatide once weekly for the Treatment of obesity[J].N Engl J Med,2022,387(3):205-216.DOI:10.1056/NEJMoa2206038.
[18] Behary P,Tharakan G,Alexiadou K,et al.Combined GLP-1,Oxyntomodulin,and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes:a randomized,single-blinded,placebo-controlled study[J].Diabetes Care,2019,42(8):1446-1453.DOI:10.2337/dc19-0449.
[19] Elmaleh-Sachs A,Schwartz JL,Bramante CT,et al.Obesity management in adults:a review[J].JAMA,2023,330(20):2000-2015.DOI:10.1001/jama.2023.19897.
[20] Lewis KH,Moore JB,Ard JD.Game changers:do new medications make lifestyle-based treatment of obesity obsolete?[J]Obesity(Silver Spring),2023.DOI:10.1002/oby.23962.
[21] Wadden TA,Chao AM,Moore M,et al.The role of lifestyle modification with second-generation anti-obesity medications:comparisons,questions,and clinical opportunities[J].Curr Obes Rep,2023,12(4):453-473.DOI:10.1007/s13679-023-00534-z.
[22] Flanagan EW,Spann R,Berry SE,et al.New insights in the mechanisms of weight-loss maintenance:summary from a pennington symposium[J].Obesity(Silver Spring),2023,31(12):2895-2908.DOI:10.1002/oby.23905.
[23] Ostendorf DM,Blankenship JM,Grau L,et al.Predictors of long-term weight loss trajectories during a behavioral weight loss intervention:an exploratory analysis[J].Obes Sci Pract,2021,7(5):569-582.DOI:10.1002/osp4.530.